Allakos Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Allakos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View analyst ratings for Allakos or view top-rated stocks.

10 brokerages have issued 12-month target prices for Allakos' shares. Their ALLK stock forecasts range from $13.00 to $155.00. On average, they anticipate Allakos' share price to reach $68.42 in the next twelve months. This suggests a possible upside of 2,165.6% from the stock's current price.
View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts.

Allakos' stock was trading at $9.79 at the beginning of 2022. Since then, ALLK stock has decreased by 69.2% and is now trading at $3.02.
View the best growth stocks for 2022 here.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Allakos.

Allakos Inc. (NASDAQ:ALLK) released its earnings results on Friday, May, 6th. The company reported ($3.60) EPS for the quarter, missing the consensus estimate of ($1.71) by $1.89.
View Allakos' earnings history.

Some companies that are related to Allakos include TG Therapeutics (TGTX), POINT Biopharma Global (PNT), Evolus (EOLS), Nuvalent (NUVL), Northwest Biotherapeutics (NWBO), Organogenesis (ORGO), Gossamer Bio (GOSS), Ventyx Biosciences (VTYX), Mirum Pharmaceuticals (MIRM), Vanda Pharmaceuticals (VNDA), Geron (GERN), DICE Therapeutics (DICE), Collegium Pharmaceutical (COLL), Atea Pharmaceuticals (AVIR) and Zealand Pharma A/S (ZEAL).
View all of ALLK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $3.02.

Allakos (NASDAQ:ALLK) has a market capitalization of $165.43 million. The company earns $-269.86 million in net income (profit) each year or ($7.56) on an earnings per share basis.

Allakos employs 192 workers across the globe.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for Allakos is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.